🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re thrilled to announce our latest step forward in advancing the field of infectious disease diagnostics: A contract with BARDA that supports the extension of our capabilities to include RNA pathogen detection. Read more here: hubs.li/Q02KF_pB0? #metagenomics #HHS

We are excited to share new VBP101 clinical data that validates our approach of using shielded transplants to deliver targeted therapies, encouraging VCAR33 (ALLO) data and a new asset, VADC45. We will host an investor call today at 4:30pm ET. Read more: buff.ly/4ecLmyV

Precede Biosciences is excited to share data at #ESMO24 demonstrating our unique platform’s capability to reveal tumor PSMA expression from a simple blood test that is highly correlated with PSMA-PET imaging. View press release: bit.ly/47oot9z #PrecisionMedicine #Healthcare

#Science2Startup 2024 united academics,entrepreneurs, industry leaders & VCs for adynamic exchange of ideas. The symposium showcased exceptional scientists from global research institutions, all working on pioneering advancements in science. Learn more: science2startup.com

Today we announced two presentations highlighting data on our #influenza drug-Fc conjugate (DFC) candidate at the 2024 OPTIONS XII conference in Brisbane, Australia. Read here for more information on our oral and poster presentations: cidara.com/news/cidara-th…

Attention #biotech entrepreneurs and researchers! Don’t miss your chance to pitch your #startup ideas at #Science2Startup 2025 to top biotech and #pharma executives, VCs, and entrepreneurs in the Boston area. Applications are due Fri, Nov 15th: science2startup.com/#submissions

Today a positive data update from the Phase 1 clincal trial of ELVN-001 was presented at the ESH-iCMLf Annual John Goldman Conference. Learn more about the updated data here: bit.ly/3ZEyLQX

ELVN-001 phase 1 trial continues to show anti-CML activity in heavily pre-treated CML patients. We are energized by the progress and the potential to address the need for more efficacious and better tolerated TKIs so people with CML can not only live longer but live better.

We are excited to welcome Han Choi, MD, LLM as #VorBio’s CFO. Han’s extensive experience in healthcare investment and strategic operations will help our team advance our mission of transforming outcomes for patients with AML & other blood cancers. ir.vorbio.com/news-releases/…

We are delighted to enter this collaboration with BioMarin and leverage the capabilities of our RAP platform to identify druggable regRNA targets. Check out the full release here: camp4tx.com/camp4-enters-s…

Yesterday we announced pricing of our Initial Public Offering. Read our full press release here: camp4tx.com/camp4-announce…

Join host firms F-Prime Capital, Atlas Venture, 5AM Ventures, Osage Univ. Partners, and RA Capital Management for the 2025 #Science2Startup symposium on Wed, May 14th! Have a groundbreaking idea for a #biotech #startup? Submit your application by Fri, Nov 15th: bit.ly/4dqXc7P

FNAIT is officially on notice 📢 today, as we're announcing the approval of our lead program, RLYB212, to move into Phase 2 trials in pregnant women at higher risk of alloimmunization and FNAIT (fetal and neonatal alloimmune thrombocytopenia): investors.rallybio.com/news-releases/…

Preliminary data from Skye's newly-developed diet-induced obesity (DIO) model in mice fulfilled its initial objective of showing that peripheral CB1 inhibition achieves significant weight loss without relying on central activity and its risk of neuropsychiatric adverse events.

We are excited to unveil our 3 lead programs targeting genetic, immune and oncological diseases. These innovative programs leverage our in vivo hematopoietic stem cell engineering platform and aim to address unmet needs in #CGD, #sicklecell disease and solid tumors. We look

🚨 Today, Rallybio announced the initiation of the Phase 2 clinical trial investigating RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Today we announced a $105M private placement led by Venrock Healthcare Capital Partners, with significant participation by new and existing life-sciences focused investors. Read more here: cidara.com/news/cidara-th…

We’re pleased to announce we’ve reached full planned enrollment of 5,000 subjects in our Phase 2b NAVIGATE #ClinicalTrial across sites in the US and UK. Read more about the trial and this important milestone here: cidara.com/news/cidara-th…

Today, we celebrate a transformative milestone as the exceptional teams at Chroma Medicine and Nvelop Therapeutics unite to form nChroma Bio. Together, we are embarking on a shared mission to redefine the future of genetic medicines. Stay tuned for what’s next and be sure to follow us